A Synthesis of Policy Institute Proposals for a New Pandemic Accord After the WHO Deadline Miss and Equity Collapse

In 2022, sitting in a Geneva boardroom among diplomats discussing “global solidarity” while supply chain managers quietly positioned themselves with private stockpiles, it was obvious to anyone that the idealism reflected in the draft would never be realized against the backdrop of national self-interests. With the passage of the deadline, every CEO who thought a global treaty would address their risk management issues received a very clear message; they were on their own.

The Problem: Without a binding international agreement, a significant regulatory void exists and businesses are left trying to make sense of a fractured public health security structure that lacks a global set of rules.

The Constraints: Businesses currently work within a complex environment of competing national sovereignty, intellectual property protections, and the urgent need for equitable access to and distribution of medical countermeasures.

The Solution: Rather than continuing to hold out hope for a “top-down” international solution, companies now need to focus on “bottom-up” resiliency through decentralized supply chains and risk-mitigation strategies.

Prerequisites for Navigating This Landscape

To effectively assess this situation, you do not need a PhD in IHR. However, you do need to understand International Health Regulations (IHR) and your company’s supply chain vulnerability. In the absence of mutual agreement by the nations of the world, the burden of compliance falls squarely on your company’s risk profile.

The Post-Deadline Landscape: Why the 2026 Accord Stalled
Analyzing the Breakdown of Multilateral Health Governance

The WHO pandemic accord negotiation collapse 2026 expert proposals contain an essential truth: nations put their own citizens first during crises. The Global North wanted to protect its intellectual property, while the Global South demanded guarantees of access to life-saving technology. There has been no middle ground, and so the multilateral process has come to an end.

The Economic Impact of Regulatory Uncertainty on Global Markets

If there is no clear rulebook to back up the regulatory framework of the global markets, investors will be anxious. Investors do not like uncertainty. If you are a biotech company, you cannot predict whether or not your patents will be subject to compulsory licensing when a pandemic strikes in the future. The uncertainty increases the cost of capital for the companies and makes them hold larger cash balances, resulting in delayed innovation.

What Didn’t Work For Me

I solely relied on government-issued guidance when developing supply chain strategies earlier in my career. I believed that “official” channels would supply the PPE and vaccinations required if a pandemic occurred. I found that many of our “official” orders were confiscated at international borders and that my Logistics division was virtually bankrupt after relying solely on a single centralized source. I learned the hard way that you cannot rely on a treaty that has not been signed as a means of survival.

A Synthesis of WHO pandemic accord negotiation collapse 2026 expert proposals
Reconciling Sovereignty with Collective Security Frameworks

Policy researchers today are advocating a “modular approach.” Have proposed amendments to the Accord in the form of smaller regional treaties that allow for countries to maintain their sovereignty while still agreeing to share pathogen access and benefit-sharing mechanism protocols.

Proposed Governance Models for Post-Accord Cooperation
The “Coalition of the Willing” Model: Countries form coalitions to agree on common items without needing all 190+ nations to agree.
The Private-Public Hybrid: Corporations take the lead by setting their criteria for vaccine distribution, and governments serve as regulatory agents rather than distributing agents.
Pathogen Access and Benefit-Sharing: The Equity Dilemma
Redefining the Pathogen Access and Benefit-Sharing Mechanism

The core issue is how we share digital sequence information (DSI) regarding viruses. The country providing the virus sample expects to receive the resulting vaccine from any pharmaceutical company. The current proposal suggests creating a global fund where pharmaceutical companies pay a sales tax in exchange for access to virus samples.

Balancing Intellectual Property Rights with mRNA Technology Transfer

This is where the greatest tension lies. Regarding mRNA technology transfer, the established global south considers this to be the “holy grail.” Policy advisors support a tiered licensing model:

Tier 1: High-income markets pay full IP prices.
Tier 2: Middle-income markets receive subsidized access.
Tier 3: Low-income markets will have royalty-free manufacturing rights during the first reported state of emergency.
Infrastructure and Surveillance: Beyond the Accord
Scaling the Global South Vaccine Manufacturing Hub

It is critical that we stop using the “hub-and-spoke” system in which all production occurs in either Europe or the US. The creation of a Global South vaccine manufacturing hub will develop regional resilience. This approach is not only good for philanthropy but also provides a new business model, as the development of regional hubs shortens supply chains and mitigates the risk of export bans for products manufactured in Europe or the US.

Financing the AMR Surveillance Fund and Zoonosis Risk Spillover Mitigation

There has been increased emphasis on creating an AMR surveillance fund as a way to track antimicrobial resistance. Additionally, monitoring zoonosis risk spillover (from animals to humans) is now a key component of corporate ESG (environmental, social, and governance) reporting. Failure to track these risks will eventually lead to investor dissatisfaction.

Operational Resilience: Supply Chain and Strategic Reserves
The Shift Toward Decentralized PPE Strategic Reserve Stockpile Management

Centralized stockpiles are the definition of “sitting ducks”. If your government controls the stockpile, you may never receive your allocation. The emerging trend is to decentralize the management of PPE strategic reserve stockpile. Many companies now maintain “buffer stocks” of PPE in multiple geographic areas to ensure that they can continue operating, even if borders are closed.

Integrating IHR Amendment Implementation into Corporate Risk Profiles

Implementation of IHR amendment implementation should be treated as part of your fundamental corporate metrics. When international regulations change, your internal compliance systems should automatically reflect those changes.

Edge Case Analysis: The Private Sector “Shadow Accord”
Navigating Undocumented Workarounds for Cross-Border Health Compliance

When treaties have failed, businesses will develop “shadow” methods of collaborating. Private agreements between large pharmaceutical companies and logistics companies to share information to bypass bureaucratic constraints are examples of shadow methods. This is not an ideal solution, but at least it allows for continued service.

Mitigating Liability When Multilateral Treaties Fail to Materialize

As a CEO, it is necessary to change your force majeure clauses. A force majeure clause cannot be based on “government failure” as an excuse for a failure in the supply chain. You must demonstrate that you have put in place proactive measures to secure your own supply chain.

Frequently Asked Questions
How does the collapse of the accord affect long-term investment in biotech and pharmaceutical sectors?

It creates a “wait and see” environment. Investors are favoring companies that have diversified their manufacturing profiles and do not rely on any one government’s regulatory approval process.

What should business leaders prioritize in their pandemic preparedness planning given the lack of a unified global framework?

The top priority needs to be on supply chain visibility. You have to be aware of exactly how and where you are getting your raw materials and have a back-up plan for every single component.

How can private enterprises align with the proposed Global South manufacturing initiatives to ensure supply chain continuity?

Private enterprises should be searching for partnerships with manufacturers in their area. Providing technical assistance in exchange for local manufacturing capabilities gives you a reliable supply source that is closer to your customers than using a foreign source.